Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2954977 | 0.76 | MAP2K1 (0.69) | MAP2K1CA2MAP2K2 | |
| SCHEMBL391026 | 0.73 | MAP2K1 (0.51) | MAP2K1CA2MAP2K2 | |
| SCHEMBL2953672 | 0.72 | MAP2K1 (0.67) | MAP2K1CA2MAP2K2 | |
| SCHEMBL31354748 | 0.72 | MAP2K1 (0.67) | MAP2K1CA2MAP2K2 | |
| SCHEMBL1111383 | 0.70 | MAP2K1 (0.79) | MAP2K1CA2 | |
| SCHEMBL27470937 | 0.70 | MAP2K1 (0.55) | MAP2K1MAP2K2 | |
| SCHEMBL1111473 | 0.70 | MAP2K1 (0.68) | MAP2K1MAP2K2 | |
| SCHEMBL30022485 | 0.68 | MAP2K1 (0.63) | MAP2K1MAP2K2 | |
| SCHEMBL12540033 | 0.67 | MAP2K1 (0.51) | MAP2K1CA2MAP2K2 | |
| SCHEMBL24539656 | 0.67 | MAP2K1 (0.64) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022076-A1 | DERIVATIVES OF N-(ARYLAMINO)SULFONAMIDES AS INHIBITORS OF MEK | MADERNA ANDREAS (US) | 2012-01-26 | — | — | US | disclosed |
| US-8101799-B2 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110060049-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | ARDEA BIOSCIENCES, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | ARDEA BIOSCIENCES, INC (US) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022076-A1 | DERIVATIVES OF N-(ARYLAMINO)SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAP2K1 52/4885CA2 4520/4885MAP2K2 48/4885 |
| US-20110060049-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES INCLUDING POLYMORPHS AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND METHODS FOR PREPARING THE SAME | NRAS, BRAF, MAP3K2 | MAP2K1 28/4885CA2 3020/4885MAP2K2 21/4885 |
| US-20110033539-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | HMGCR, PCSK9, C5 | MAP2K1 4649/4885CA2 999/4885MAP2K2 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.